Please assess the completion status of the following clinical trial:

Trial Title: Lanreotide Autogel in the Treatment of Symptomatic Polycystic Liver Disease

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Liver volume ≥ 4 liter~* ≥ 20 liver cysts~* Symptomatic patients defined as at least 2 out of 5 of the following symptoms related to mass effect irrespective of the intensity:~  * Abdominal distention perceived as uncomfortable~ * Frequent abdominal pain~ * Early satiety~ * Nausea (with the inclusion of dyspeptic complaints)~ * Dyspnea~* Diagnosed with ADPKD or ADPLD~* Male and female patients of 18 years and older~* Written informed consent~Exclusion Criteria:~* Creatinine clearance \< 20 ml/min~* Patient who underwent a kidney transplant and received variable doses of immunosuppressive therapy and/or present signs of rejection in the past year~* Hormonal replacement therapy~* Hormonal contraception~* Pregnant or lactating~* Presenting with an uncontrolled disease (other than ADPKD/ADPLD)~* Planned to undergo any surgery of the liver during study participation~* Planned to undergo any surgery of the KIDNEY during study participation (ADPKD patients only)~* Patients with known allergies to somatostatin or its analogues or any of its components~* Patients who received somatostatin analogues in the 6 months preceding study inclusion

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Symptomatic polycystic liver disease (PCLD) patients (Type: EXPERIMENTAL): Symptomatic polycystic liver disease (PCLD) patients

Based on this trial design, predict the completion outcome and termination type (if applicable).